CA2633291A1 - Diagnostic de sepsie - Google Patents

Diagnostic de sepsie Download PDF

Info

Publication number
CA2633291A1
CA2633291A1 CA002633291A CA2633291A CA2633291A1 CA 2633291 A1 CA2633291 A1 CA 2633291A1 CA 002633291 A CA002633291 A CA 002633291A CA 2633291 A CA2633291 A CA 2633291A CA 2633291 A1 CA2633291 A1 CA 2633291A1
Authority
CA
Canada
Prior art keywords
biomarkers
biomarker
features
sepsis
listed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002633291A
Other languages
English (en)
Inventor
Richard L. Moore
Song Shi
William A. Nussbaumer
Craig C. Whiteford
Thomas M. Gentle
James A. Garrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Becton Dickinson and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2633291A1 publication Critical patent/CA2633291A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La présente invention concerne des procédés et un appareil pour la prédiction du développement de sepsie chez un sujet à risque pour le développement de sepsie. Des caractéristiques dans un profil de biomarqueur du sujet sont évaluées. Le sujet est susceptible de développer une sepsie si les caractéristiques correspondent à un ensemble de valeurs particulières. L'invention concerne des procédés et un appareil pour la prédiction de développement d'un stade de sepsie chez un sujet à risque pour le développement de sepsie. Une pluralité de caractéristiques dans un profil de biomarqueur est évaluée. Le sujet est susceptible de présenter un stade de sepsie si les valeurs de ces caractéristiques correspondent à un ensemble de valeurs particulières. L'invention concerne des procédés et un appareil pour le diagnostic de sepsie chez un sujet. Une pluralité de caractéristiques dans un profil de biomarqueur est évaluée. Le sujet est susceptible de développer une sepsie lorsque la pluralité de caractéristiques correspond à un ensemble de valeurs particulières.
CA002633291A 2005-12-15 2006-12-14 Diagnostic de sepsie Abandoned CA2633291A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75119705P 2005-12-15 2005-12-15
US60/751,197 2005-12-15
US81998306P 2006-07-10 2006-07-10
US60/819,983 2006-07-10
PCT/US2006/047737 WO2007078841A2 (fr) 2005-12-15 2006-12-14 Diagnostic de sepsie

Publications (1)

Publication Number Publication Date
CA2633291A1 true CA2633291A1 (fr) 2007-07-12

Family

ID=38228754

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002633291A Abandoned CA2633291A1 (fr) 2005-12-15 2006-12-14 Diagnostic de sepsie

Country Status (5)

Country Link
EP (1) EP1963527A2 (fr)
JP (1) JP2009525462A (fr)
AU (1) AU2006333077A1 (fr)
CA (1) CA2633291A1 (fr)
WO (1) WO2007078841A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007036678B4 (de) * 2007-08-03 2015-05-21 Sirs-Lab Gmbh Verwendung von Polynukleotiden zur Erfassung von Genaktivitäten für die Unterscheidung zwischen lokaler und systemischer Infektion
AU2011334548B2 (en) * 2010-11-26 2016-06-09 Immunexpress Pty Ltd Diagnostic and/or screening agents and uses therefor
ES2656150T3 (es) 2011-11-14 2018-02-23 Universitätsklinikum Jena Diagnóstico de la sepsis y del síndrome de respuesta inflamatoria sistémica
US9759729B2 (en) 2012-06-08 2017-09-12 The Board Of Trustees Of The Leland Stanford Junior University Blood biomarkers for necrotizing enterocolitis
US20230165941A1 (en) * 2018-10-22 2023-06-01 Asahi Kasei Pharma Corporation Medicament for therapeutic treatment and/or improvement of sepsis accompanied by coagulopathy
JP6954568B2 (ja) * 2020-03-31 2021-10-27 クラシエホールディングス株式会社 健康管理支援システム、健康管理支援方法、及びプログラム

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465542B2 (en) * 2002-10-15 2008-12-16 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining risk of treatment toxicity
US20040096917A1 (en) * 2002-11-12 2004-05-20 Becton, Dickinson And Company Diagnosis of sepsis or SIRS using biomarker profiles
JP4643445B2 (ja) * 2002-11-12 2011-03-02 ベクトン，ディッキンソン アンド カンパニー バイオマーカープロフィールを使用した敗血症またはｓｉｒｓの診断
CN1742087A (zh) * 2002-11-12 2006-03-01 贝克顿迪金森公司 使用生物标记谱诊断脓毒或者sirs
EP1587955A4 (fr) * 2002-12-24 2007-03-14 Biosite Inc Marqueurs de diagnostic differentiel et procedes d'utilisation
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
WO2005033327A2 (fr) * 2003-09-29 2005-04-14 Biosite Incorporated Procedes et compositions pour le diagnostic du sepsis

Also Published As

Publication number Publication date
EP1963527A2 (fr) 2008-09-03
WO2007078841A2 (fr) 2007-07-12
JP2009525462A (ja) 2009-07-09
AU2006333077A1 (en) 2007-07-12
WO2007078841A3 (fr) 2009-04-09

Similar Documents

Publication Publication Date Title
US20090104605A1 (en) Diagnosis of sepsis
US11578367B2 (en) Diagnosis of sepsis
US20220325348A1 (en) Biomarker signature method, and apparatus and kits therefor
CN101622360A (zh) 脓毒症的诊断
EP2574679A2 (fr) Procédés de pronostic carninoma hépatocellulaire in vitro
US20070281300A1 (en) Thrombomodulin (Thbd) Haplotypes Predict Outcome
US20190085407A1 (en) Methods and compositions for diagnosis of glioblastoma or a subtype thereof
Zhang et al. A rare missense variant of CASP7 is associated with familial late-onset Alzheimer's disease
CA2718741A1 (fr) Procede de detection et de differenciation in vitro d'etats pathophysiologiques
WO2009134452A2 (fr) Analyse de diagnostic d'accouchement prématuré
KR20180009762A (ko) 폐암을 진단하거나 검출하기 위한 방법 및 조성물
US20110086796A1 (en) Methods for predicting the development and resolution of acute respiratory distress syndrome
CA2633291A1 (fr) Diagnostic de sepsie
CN115418401A (zh) 用于膀胱癌的尿监测的诊断测定
WO2018146162A1 (fr) Biomarqueur moléculaire pour le pronostic de patients atteints de septicémie
WO2011082392A1 (fr) Biomarqueurs géniques de la fonction pulmonaire
US20030162207A1 (en) Multi-gene tests with ROC plots for the assessment of risk for polygenic disorders
CN112585281A (zh) 用于阿尔茨海默氏病的小rna预测因子
WO2015117205A1 (fr) Méthode de signature de biomarqueur, et appareil et kits associés
US20140194310A1 (en) Genes dysregulated in autism as biomarkers and targets for therapeutic pathways
US20090092987A1 (en) Polymorphic Nucleic Acids Associated With Colorectal Cancer And Uses Thereof
Bartels et al. Real time PCR detection of the PI* Z and PI* S mutations associated with alpha-1 antitrypsin deficiency
US20130040846A1 (en) Signatures for Kidney Aging
CN117417999A (zh) 一种与ireb2基因相关的snp分子标记及其应用
WO2016198684A1 (fr) Biomarqueur moléculaire pour le diagnostic d'une pneumonie extra-hospitalière à l'admission en unité de soins intensifs

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20101214